These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29845398)

  • 1. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
    Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
    Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
    Han SA; Jang JH; Won KY; Lim SJ; Song JY
    Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
    Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
    Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.
    Henderson T; Chen M; Darrow MA; Li CS; Chiu CL; Monjazeb AM; Murphy WJ; Canter RJ
    J Surg Res; 2018 Mar; 223():207-214. PubMed ID: 29433875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
    DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
    Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
    Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
    Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
    Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
    Nakshatri H; Srour EF; Badve S
    Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cancer stem cell markers in breast phyllodes tumor.
    Kim SI; Koo JS
    Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer.
    Huang HH; Wang YC; Chou YC; Yu MH; Chao TK
    PLoS One; 2018; 13(10):e0206685. PubMed ID: 30372483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
    DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
    Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
    Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
    Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.